Sussex NHS Trust transitions MT-RNR1 test to BAU

Genedrive PLC

05 May 2026

 

5 May 2026

genedrive plc

("genedrive" or the "Company")

University Hospitals Sussex NHS Foundation Trust transitions genedrive's MT-RNR1 test to Business as Usual clinical service

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that, from 1 May 2026, University Hospitals Sussex NHS Foundation Trust ("UHS") hospitals transitioned to Business as Usual ("BAU") routine clinical service of the Genedrive® MT-RNR1 ID kit for the prevention of Antibiotic Induced Hearing Loss ("AIHL") in neonates admitted to Neonatal Intensive Care Units ("NICU").

UHS Royal County Sussex Hospital's Trevor Mann Baby Unit provides specialist care for approximately 400 NICU admissions annually and has been a participating site in the PALOH-UK programme, which aims to address National Institute for Clinical Care and Excellence ("NICE") Real World Evidence generation requirements. To date, nearly 40 babies in NICUs have been identified with the MT-RNR1 variant since introduction of the test in the UK, enabling alternative antibiotic prescription and reducing the risk of aminoglycoside-induced lifelong hearing loss.

Dr Gino Miele, CEO of genedrive plc, said: "The transition to BAU routine clinical service at UHS is a key milestone in driving wider scale adoption of our MT-RNR1 genetic test in the UK. UHS was an early adopter of this test prior to the initiation of the PALOH-UK programme and has been a key supporter of genedrive's technology. Since its introduction in the region, the test has had clear impact, identifying several babies who otherwise would have been at risk of lifelong hearing loss. We are delighted that babies and families in this region of NHS England will continue to benefit from the routine availability of our test.

"We are in active discussions with other hospitals in the PALOH-UK programme to support the transition of our MT-RNR1 test from PALOH-UK based funding to embedding into routine practice to ensure that newborn babies across the UK continue to have access to this preventive test."

Funding for PALOH-UK sites is provided by the Office for Life Sciences ("OLS") and National Institute for Health and Care Research ("NIHR") and will cease by June 2026, with some sites completing earlier. Subsequent review and issuance of final guidance by NICE is expected around July 2027.

genedrive plc	[phone]
Gino Miele: CEO / Russ Shaw: CFO	https://investors.genedrive.com/s/e0025c
Peel Hunt LLP (Nominated Adviser and Broker)	[phone]
James Steel
5654 & Company  (Media & Investor Relations)	[e-mail]
Matthew Neal	[phone]
Melissa Gardiner	[phone]

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03 

About genedrive plc (http://www.genedrive.com).

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.

 

END